Longeveron scores RMAT designation for Alzheimers cell therapy – Pharmaceutical Technology

The US Food and Drug Administration (FDA) has awarded a Regenerative Medicine Advanced Therapy (RMAT) designation to Longeverons Lomecel-B for treating mild Alzheimers Disease.

An RMAT designation provides the benefits of both fast track and breakthrough designations, thereby, allowing for accelerated approval based on surrogate or intermediate endpoints. It also allows for multiple meetings with the FDA to expedite drug development.

Following the news, Longeveron stock was up by over 20% in pre-market trading today, compared to the market close on 9 July.

Lomecel-B is made up of human mesenchymal stem cells, derived from the bone marrow of healthy human donors. It is being evaluated as a treatment for hypoplastic left heart syndrome, and ageing-related frailty, in addition to Alzheimers disease.

Lomecel-B met the primary safety endpoint in a Phase II CLERMIND trial (NCT05233774), which enrolled 50 patients with mild Alzheimers. There were three reported serious events within 30 days of Lomecel-B administration, one in each of three different treatment dose groups, compared to none in the placebo group.

There were no incidences of hypersensitivity, notable changes in laboratory evaluations and electrocardiogram (EKG), or cases of amyloid-related imaging abnormalities (ARIA). Additionally, no clinically asymptomatic microhaemorrhages were noted on MRI. The therapy also improved cognitive functions and reduced neuroinflammation assessed by diffusion tensor imaging, an MRI imaging technique.

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Your download email will arrive shortly

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

Country * UK USA Afghanistan land Islands Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bonaire, Sint Eustatius and Saba Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos Islands Colombia Comoros Congo Democratic Republic of the Congo Cook Islands Costa Rica Cte d"Ivoire Croatia Cuba Curaao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and McDonald Islands Holy See Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati North Korea South Korea Kuwait Kyrgyzstan Lao Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macedonia, The Former Yugoslav Republic of Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia Moldova Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Northern Mariana Islands Norway Oman Pakistan Palau Palestinian Territory Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Runion Romania Russian Federation Rwanda Saint Helena, Ascension and Tristan da Cunha Saint Kitts and Nevis Saint Lucia Saint Pierre and Miquelon Saint Vincent and The Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and The South Sandwich Islands Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syrian Arab Republic Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates US Minor Outlying Islands Uruguay Uzbekistan Vanuatu Venezuela Vietnam British Virgin Islands US Virgin Islands Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe Kosovo

Industry * Academia & Education Aerospace, Defense & Security Agriculture Asset Management Automotive Banking & Payments Chemicals Construction Consumer Foodservice Government, trade bodies and NGOs Health & Fitness Hospitals & Healthcare HR, Staffing & Recruitment Insurance Investment Banking Legal Services Management Consulting Marketing & Advertising Media & Publishing Medical Devices Mining Oil & Gas Packaging Pharmaceuticals Power & Utilities Private Equity Real Estate Retail Sport Technology Telecom Transportation & Logistics Travel, Tourism & Hospitality Venture Capital

Tick here to opt out of curated industry news, reports, and event updates from Pharmaceutical Technology.

Submit and download

The global market for Alzheimers treatments is expected to be worth over $15.9bn in 2030, as per a GlobalData report. The field is dominated by amyloid-targeting therapies, with Eli Lillys Kisunla (donanemab) being the latest FDA-approved therapy in this class.

GlobalData is the parent company of Pharmaceutical Technology.

The news comes as a welcome reprieve for the company after it discontinued a Phase II trial of Lomecel-B in ageing-related frailty in Japan, in February. The decision was a strategic move by the Longeveron to focus on developing Lomecel-B in hypoplastic left heart syndrome, a rare congenital heart defect.

The company is evaluating Lomecel-B in a Phase IIb ELPIS II trial (NCT04925024) in hypoplastic left heart syndrome patients under 12 years of age. The trial plans to recruit 38 participants, with enrolment expected to be completed by the end of the year.

Stem cell treatments are a relatively new area in the Alzheimers treatment space. Regeneration Biomedical is evaluating its autologous stem cell treatment, RB-ADSC, in mild-to-moderate Alzheimers in a Phase I trial (NCT05667649).

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Editorial content is independently produced and follows thehighest standardsof journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Give your business an edge with our leading industry insights.

See more here:
Longeveron scores RMAT designation for Alzheimers cell therapy - Pharmaceutical Technology